Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take existing Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device malfunctions, which have reportedly caused serious risks to patients [2][4]. Group 1: Allegations and Impact - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that led to malfunctions, including underinfusion and overinfusion, posing risks of serious injury or death to patients [4]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to a heightened risk of customers removing the Novum LVPs from service and pausing new sales [4]. - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price fell by 22.4%, closing at $21.76 [5]. Group 2: Legal Proceedings - Investors who suffered losses exceeding $100,000 in Baxter between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Baxter is December 15, 2025 [2][6]. - Faruqi & Faruqi is also inviting anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to come forward [6].

CONTACT US HERE:https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form- 2/?id=174900&from=4 CLASS PERIOD: February 23, 2022 to July 30, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Baxter's recently launched product, the Novum LVP, suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-del ...

Core Insights - Baxter International Inc. has a market capitalization of $9.5 billion and specializes in medical products and therapies, focusing on renal care, medication delivery, and pharmaceuticals [1] Stock Performance - Over the past 52 weeks, Baxter's stock has decreased by 48.5%, significantly underperforming the S&P 500 Index, which gained 17.7% during the same period [2] - Year-to-date, Baxter's stock has fallen 36.7%, while the S&P 500 has risen by 16.3% [2] Sector Comparison - Baxter's shares have also underperformed compared to the Health Care Select Sector SPDR Fund, which saw a 2.6% drop over the past 52 weeks [3] Financial Performance - In Q3 2025, Baxter reported an adjusted EPS of $0.69, which was better than expected, but the stock plunged 14.5% due to revenue of $2.84 billion missing forecasts [4] - The company has cut its full-year adjusted EPS guidance to a range of $2.35 - $2.40 and reduced expected sales growth to 4% - 5% due to hurricane-related disruptions [4] Analyst Expectations - Analysts expect Baxter's adjusted EPS for the current fiscal year to grow by 24.9% year-over-year to $2.36 [5] - The consensus rating among 16 analysts covering the stock is a "Hold," with two "Strong Buy" ratings, 13 "Holds," and one "Moderate Sell" [5] Price Target Adjustments - Goldman Sachs has cut Baxter's price target to $22 while maintaining a "Neutral" rating [7] - The mean price target of $26.77 suggests a 44.9% premium to the current price, while the highest price target of $40 indicates a potential upside of 116.6% [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, about the upcoming lead plaintiff deadline of December 15, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific issues included malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, which Baxter was aware of but did not adequately address [5] - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP device, which has been linked to serious patient risks and malfunctions [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Baxter, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks of serious injury or death to patients [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [5]. Group 3: Stock Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [6].

Trade Relations - President Trump and President Xi Jinping agreed to extend a tariff truce, roll back export controls, and reduce other trade barriers, including cutting fentanyl-related tariffs on Chinese goods from 20% to 10% [1] - China will resume purchases of US agricultural products such as soybeans and sorghum, while pausing controls on rare-earth magnets in exchange for the US rolling back restrictions on Chinese companies [1] Market Sentiment - US stock indexes closed higher, driven by positive corporate earnings, with Amazon.com leading the way with a more than 9% increase after reporting strong earnings [4][5] - Over 80% of S&P 500 companies that reported Q3 earnings have beaten estimates, indicating a bullish market sentiment [6] Economic Indicators - The markets are anticipating a 64% chance of a 25 basis point rate cut at the next FOMC meeting, with an overall expected cut of 82 basis points by the end of 2026 [2] - The October MNI Chicago PMI rose by 3.2 points to 43.8, exceeding expectations, which is supportive for stocks [3] Corporate Earnings - Q3 profits for S&P 500 companies are expected to rise by 7.2% year-over-year, the smallest increase in two years, while sales growth is projected to slow to 5.9% year-over-year [6] - Notable corporate earnings include Amazon.com with Q3 net sales of $180.17 billion, exceeding the consensus of $177.82 billion, and forecasting Q4 net sales of $206 billion to $213 billion [14] Government Impact - The ongoing US government shutdown is affecting market sentiment and delaying the release of key economic reports, with an estimated 640,000 federal workers furloughed [8] - The shutdown could lead to increased jobless claims and a rise in the unemployment rate to 4.7% [8] International Markets - Overseas stock markets showed mixed results, with the Euro Stoxx 50 down 0.65% and China's Shanghai Composite down 0.81%, while Japan's Nikkei Stock 225 rose sharply by 2.12% [9]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Insights - Baxter International Inc. is a global healthcare company providing essential medical products, including devices, pharmaceuticals, and biotechnology, with a focus on Medical Products and Therapies [1] - The company faces competition from major players like Johnson & Johnson and Medtronic [1] Financial Performance - Baxter reported a third-quarter adjusted EPS of 69 cents, exceeding management's guidance of 58-62 cents and Wall Street's estimate of 60 cents [3] - The company's sales for the third quarter were $2.84 billion, reflecting a 5% year-over-year increase on a reported basis and a 2% increase on an operational basis, closely aligning with the consensus of $2.88 billion [4] - Despite the positive EPS results, Baxter lowered its 2025 guidance, which negatively impacted investor sentiment [3][6] Segment Performance - The Medical Products and Therapies segment reported sales of approximately $1.33 billion, showing a 1% decline on both a reported and operational basis, primarily due to reduced sales in the Infusion Therapies and Technologies division [5][6] - Strong global demand for other products partially offset the decline in the Medical Products and Therapies segment [5] Market Outlook - Stifel Nicolaus set a price target of $22 for Baxter, indicating a potential upside of approximately 14.73% from the current stock price of $19.18 [2] - Despite the optimistic price target, Baxter's stock has experienced a significant drop, reaching a 52-week low [2][6]